Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema

被引：31

作者：

Cohn, Danny M. ^{[1
]}

Viney, Nicholas J. ^{[4
]}

Fijen, Laure M. ^{[1
]}

Schneider, Eugene ^{[4
]}

Alexander, Veronica J. ^{[4
]}

Xia, Shuting ^{[4
]}

Kaeser, Gwendolyn E. ^{[4
]}

Nanavati, Charvi ^{[4
]}

Baker, Brenda F. ^{[4
]}

Geary, Richard S. ^{[4
]}

Levi, Marcel ^{[5
,6
,7
]}

Meijers, Joost C. M. ^{[2
,3
]}

Stroes, Erik S. G. ^{[1
]}

机构：

[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands

[2] Univ Amsterdam, Amsterdam UMC, Dept Expt Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands

[3] Sanquin Res, Dept Mol & Cellular Hemostasis, Amsterdam, Netherlands

[4] Ionis Pharmaceut, Carlsbad, CA USA

[5] Univ Coll London Hosp NHS Fdn Trust, Dept Med, London, England

[6] Univ Coll London Hosp, Natl Inst Hlth Res, Cardiometab Programme, London, England

[7] UCL, Biomed Res Ctr, London, England

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 13期

关键词：

PLASMA KALLIKREIN; DEFICIENCY;

D O I：

10.1056/NEJMoa1915035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hereditary angioedema is characterized by recurrent and unpredictable episodes of subcutaneous and mucosal swelling that can be life threatening. IONIS-PKK-L-Rx is a ligand-conjugated antisense oligonucleotide designed for receptor-mediated delivery to hepatocytes. In a compassionate-use pilot study, two patients with severe bradykinin-mediated angioedema were initially administered weekly subcutaneous injections of the unconjugated parent drug, IONIS-PKKRx, for 12 to 16 weeks, after which they received IONIS-PKK-L-Rx at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months. Treatment was accompanied by a reduction in the angioedema attack rate.

引用

页码：1242 / 1247

页数：6

共 50 条

[31] Lanadelumab for the treatment of hereditary angioedema
Wu, Maddalena Alessandra
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (12) : 1233 - 1245
[32] Current and Emerging Therapies to Prevent Hereditary Angioedema Attacks
Lumry, William R.
AMERICAN JOURNAL OF MANAGED CARE, 2018, 24 (14) : S299 - S307
[33] Hereditary angioedema with a mutation in the plasminogen gene
Bork, K.
Wulff, K.
Steinmueller-Magin, L.
Braenne, I.
Staubach-Renz, P.
Witzke, G.
Hardt, J.
ALLERGY, 2018, 73 (02) : 442 - 450
[34] Use of Ecallantide in Pediatric Hereditary Angioedema
MacGinnitie, Andrew J.
Davis-Lorton, Mark
Stolz, Leslie E.
Tachdjian, Raffi
PEDIATRICS, 2013, 132 (02) : E490 - E497
[35] International consensus on hereditary and acquired angioedema
Lang, David M.
Aberer, Werner
Bernstein, Jonathan A.
Chng, Hiok Hee
Grumach, Anete Sevciovic
Hide, Michihiro
Maurer, Marcus
Weber, Richard
Zuraw, Bruce
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (06) : 395 - 402
[36] Hereditary angioedema: Two case reports
Haddad, M.
Ghrairi, N.
Kallel, M.
Tritar, F.
Yalaoui, S.
IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2012, 27 (02): : 66 - 68
[37] Clinical manifestations of hereditary angioedema and a systematic review of treatment options
Rosi-Schumacher, Mattie
Shah, Sejal J.
Craig, Timothy
Goyal, Neerav
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2021, 6 (03): : 394 - 403
[38] Summary and future of medicine for hereditary angioedema
Ding, Lei
Zhang, Meng-Jiao
Rao, Guo-Wu
DRUG DISCOVERY TODAY, 2024, 29 (03)
[39] Acute Management of Hereditary Angioedema Attacks
Katelaris, Constance H.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (03) : 541 - +
[40] Lanadelumab for the prevention of attacks in hereditary angioedema
Valerieva, Anna
Senter, Riccardo
Wu, Maddalena Alessandra
Zanichelli, Andrea
Cicardi, Marco
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (12) : 1239 - 1248

← 1 2 3 4 5 →